Education

Inside Track: Pathology and Patient Safety

At the end of February 2014, a group of anatomic pathology experts from leading healthcare institutions around the globe gathered at the Tucson headquarters of Ventana Medical Systems Inc. (Ventana) to examine laboratory-based patient safety issues and work toward a consensus on how to advance the standard of care for patients.

READ MORE

 

International panel of pathology leaders develop principles for patient safety

On February 27, 2014, an international panel of leaders in the pathology community announced its support of four principles designed to drive positive change and improve patient safety in the anatomic pathology laboratory. At the invitation of Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, the panel convened to examine the state of lab-based patient safety, with the challenge to work toward a consensus on how to advance the standard of care for patients.

READ MORE

 

International pathology patient safety advisory board

Ventana Medical Systems. Inc. convened an international panel of leaders in the pathology community to examine the state of lab-based patient safety, with the challenge to work toward a consensus on how to advance the standard of care for patients.

Congressional Briefing explores critical patient safety issues in anatomic pathology labs

A Congressional Briefing in Washington in November of 2012 explored critical patient safety issues related to tissue slide processing that often get overlooked in US clinical and anatomic laboratories. The Briefing was designed to educate federal legislators and their staffs about patient safety issues as they consider related legislation, regulatory oversight, and constituent service.

Often-overlooked patient safety risks in medical laboratories take center stage in effort to continue to improve US standards

Rep. Ron Barber (Dem-Arizona) delivered opening remarks for the Briefing before introducing Mara G. Aspinall, President, Ventana Medical Systems, Inc. Aspinall moderated a distinguished panel including Maurie Markman, MD, Senior Vice President of Clinical Affairs/National Director of Medical Oncology, Cancer Treatment Centers of America; Eric Walk, MD, FCAP, Senior Vice President, Medical & Scientific Affairs, Ventana; and Patricia McGaffigan, RN, MS, Interim President National Patient Safety Foundation.

 

Learn More:

Clinical Lab Products Magazine overview of the Congressional briefing

Medical Laboratory Observer Magazine: Patient safety and cancer: the dialogue begins on Capitol Hill

 

Highlights of the Briefing can be found below:

http://www.youtube.com/watch?v=uIJATxSROMk

http://www.youtube.com/watch?v=smtatmrDktk

 

A new study assesses the rates of extraneous tissue contamination of H&E linear staining procedure

Measurement of stainer bath contamination and evaluation of common mitigation strategies published in Journal of Histotechnology, (Vol 35, Number 3, September 2012, pp. 130-139(10), investigates the levels of tissue cross contamination in the histology laboratory.

READ MORE

 

Journal of Histotechnology Reports on Real Risk of Errors in Patient Tissue Biopsy Processing

Ventana Medical Systems. Inc. announced a groundbreaking study in the Journal of Histotechnology that indicates there is a real risk that errors can be made in the processing of biopsy tissue.

Study shows normal histological practices could be dramatically improved to minimize patient safety risks

A new approach to minimize the problem of patient to patient contamination in histology, published in Australian Journal of Medical Science (Vol 33 Number 2, May, 2012) comprehensively examines the tissue handling and staining, and identifies sources of tissue cross contamination during these processes, along with the diagnostic dilemmas it creates.

READ MORE

 

Occult mix ups of specimens, study shows, occur in about 1 in 100 prostate biopsies

Rate of Occult Specimen Provenance Complications in Routine Clinical Practice, published in the American Society for Clinical Pathology (January 2013; 139 (1)), evaluates a data set of almost 13,000 prostate biopsies that were prospectively tested for specimen provenance errors as part of routine clinical practice. The frequency of occult type 1 errors (a complete transposition between patients) and type 2 errors (contamination of the patient's tissue with 1 or more unrelated patients) was 0.26% and 0.67%.

READ MORE